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INTRODUCTION 
LABC refers to a diverse and heterogenous group of people with 
breast cancer which represents one of the commonest malignancy of female 
population in our region. 
 
Patients with this cancer include those with operability  at 
presentation, and inoperability at presentation. Which include stage IIb, IIIa 
and IIIb. This study also included supra clavicular node in the locally 
advanced breast cancers.1 
 
Over the past few decades, the management of the LABC has 
considerably evolved from radical mastectomy alone to multidisciplinary 
modalities involving surgery, chemotherapy and radiotherapy(RT) . With the 
advent of Neo adjuvant Chemotherapy many of the previously inoperable 
tumours have become amenable to surgery. 
 
Preoperative administration of hormonal therapy or systemic 
chemotherapy can result in considerable fall in tumour size in 50% to 80% 
of the LABC. Patients living with LABC have poor prognosis when treated 
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with surgery or RT. They include Stage IIb, III A and III B according to the 
American Joint Committee on Cancer (AJCC). 
 
As a consequence of these poor outcome neo adjuvant chemotherapy 
has been introduced. This approach is designed to render patients operable, 
and to eradicate micro metastases at an early stage,. In General only 3-4 
cycles of conventional doses of Neo adjuvant Chemotherapy given prior to 
surgery. Hekmen et al showed that clinical response rate to Neo adjuvant 
chemotherapy varies between 80% and 90% . 
 
The Neo adjuvant chemotherapy (NACT) enhanced the quality of life 
of LABC patients. NACT  reduced the morbidity and improved the overall 
survival rate and disease free interval. 
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AIM AND OBJECTIVES 
 
1. To determine the role and outcome of Neo adjuvant chemotherapy 
administered in Locally Advanced Breast Cancer (LABC). 
2. To determine and study what extend the inoperable LABC become 
amenable to surgery. 
3. To evaluate the role of NACT in improving the quality of Life, 
morbidity in LABC patients. 
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LIMIATATIONS OF THE STUDY 
 
1. This study is limited with only one Imaging modality( CT Scan) to 
predict the clinical and pathological response of tumour. 
2. Unresolved issues are there like (a) Selection of Patients, (b) 
Tumour factors, (c) Clinical factors, and (d) Regional lymph 
nodes. 
3. This study also used fixed cycles of NACT to get optimum 
response to convert inoperable tumor to an operable one. Instead of  
4-6 cycles used in the international studies we used only 3 cycles 
of chemotherapy. 
4. Some of the patients didn’t turn up for review and follow up. 
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HISTORICAL PERSPECTIVES 
Edwin Smith, surgical papyrus 3000-2500 BC was the first document 
that referred to carcinoma of Breast. The lesion was in a man but the 
description encompassed most of the features of Breast cancer. Direct 
reference to treatment of breast cancer is conspicuously absent in the corpus 
Hippocraticous. 
 
Celsus documented the value of surgical management for early breast 
cancer(EBC)  in his early Roman writings of the first century A.D. In the 2nd 
century Galens system concluded that extension of local outbreak could not 
cure the systemic imbalance. 
 
Beginning with Morgagni's systematic approach modalities that varied 
from those espoused by Galen were acceptable. In  19th century , Moore, a 
consultant worked in Middlesex Hospital placed in London enumerate wide 
removal of carcinoma breast. Bank supported Moore’s concepts. in 1894, 
Halsted & Meyer simultaneously documented their surgeries for 
management of  cancer of the Breast, the radical mastectomy. Patey of 
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Middlesex Hospital, London presented modified radical mastectomy in 
1930.3 
Samuel D Gross (b.1805) was designated as “The Greatest American 
surgeon of his  time”. His approach to carcinoma breast  was more 
conservative, using a small elliptical incision he attempted to save enough 
skin for easy approximation of the edges of the wound. 
Paget (B.1814) described cancer of nipple accompanied by the 
eczematous change and cancer of lactiferous ducts. 
Richard Von Volkmann (b.1830) removed the entire breast no matter 
how small the primary tumor, as well as the pectoral fascia with an 
occasional thick layer of the underlying muscle and the axillary nodes. 
Ernst Kuster (b.1839) of Berlin recommended that the axillary fat be 
removed along with axillary nodes. 
William Welch (b.1850) a pathologist at Johns Hopkins was the first 
to use frozen section in the diagnosis of breast lesion. 
William Halstead (b.1850) recommended “The suspected tissue to be 
removed in one piece” he advocated such wide removal of skin that a graft 
would be required and recommended that pectoralis major be part of the 
enbloc specimen regardless of the size of the tumor. This procedure 
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“Halstead’s radical mastectomy” was unchallenged for 70 years until the 
advent of  breast conservation methods. 
Wille Meyer (b.1854) described a similar technique only 10 days after 
Halstead’s published paper; he advocated removal of pectoralis minor in 
addition to pectoralis major. 
In 1937 Geoffry Keynes demonstrated that less radical surgery was 
needed in breast cancer with radiation giving good results. In 1948 two 
reports appeared that were destined to change the management of breast 
cancer. The first was the concept of modified radical mastectomy by D.Patey 
and W.Dyson. The second was treatment with simple mastectomy and 
radiotherapy by R We Whirter. 
In 1977 William Handley (b.1872) directed attention of the frequency 
of internal mammary node involvement. He reported the  removal  of  
internal mammary nodes as an extension of radical mastectomy. 
In the late years of 20th  century, Donold Morton at the John Wayne 
cancer centre in Santa Monica, CA developed the sentinel lymph node 
biopsy technique. 
Two months after the invention of X-ray, Emil Grubbe (b.1875) 
irradiated a patient with breast cancer. 
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In 1889 Albert Schinzinger (b.1927) proposed oophorectomy before 
mastectomy to produce early aging in menstruating woman. 
In 1953 Charles Huggins advocated oophorectomy and adrenalectomy 
to remove the major source of oestrogen in the body. 
 
CHANGING STRATEGIES 
In the last few decades treatment strategies for breast cancer have 
undergone significant changes. The main shift is in the concept of 
“Maximum tolerated treatment to the minimum effective treatment.” 
 
The Halstedian concept of radical mastectomy dominated the 
treatment philosophy until 4 decades ago. Breast cancer was considered as a 
local disease. In the 1960’s based on a series of randomized trials, Bernard 
Fisher proposed that Early Breast cancer is a systemic disease involving a 
complex spectrum of host tumor interactions. Hence loco regional treatment 
for breast cancer is unlikely to have an effect on survival.6 
Based on this concept, the efficacy of adjuvant chemotherapy was 
proved by studies done by Bonadone et al. and National Surgical adjuvant 
breast and Bowel Project (NSABP) 1971.7,8 
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NEOADJUVANT CHEMOTHERAPY 
Neo Adjuvant Chemotherapy was first introduced in 1973 in the 
Milan cancer institute aimed at achieving prompt tumor shrinkage.9 NSABP 
– 18 in 1988 clearly established the efficiency of Neo Adjuvant 
Chemotherapy in tumor shrinkage and thereby avoiding mutilating 
surgeries.10 
Preoperative administration of hormonal therapy or systemic 
chemotherapy can result in a considerable decline in tumor size in 50% to 
80% of patients with LABC. This neo adjuvant therapy can convert 
inoperable tumors to operable ones. Neo adjuvant chemotherapy can change 
tumors that would need for mastectomy to eligibility for lumpectomy, and 
can reduce bigger tumors to allow a more cosmetic lumpectomy. This study 
allows to evaluate tumor biology through continuous analysis of tumor 
tissue before, during, and after treatment. This is used to study the 
mechanism of action and potency of systemic chemotherapeutic agents. 
Many randomized, prospective trials analysed the effectiveness of 
hormonal therapy and chemotherapy given preoperatively (neo adjuvant) 
versus after (adjuvant) definitive surgery. All these studies documented 
increased rates of breast conservation with the use of chemotherapy 
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preoperatively. The National Surgical adjuvant breast and Bowel Project B-
18 trials included 1522 patients and found no survival advantage in patients 
who received chemotherapy preoperatively with cyclophosphamide and 
doxorubicin chemotherapy versus the same regimen administered 
randomized postoperatively. In women who received neoadjuvant 
chemotherapy had higher chance for breast conservation surgery, and 
recurrence in breast after neoadjuvant therapy was not significantly different 
from that in women who completed lumpectomy and  postoperative 
chemotherapy. Response to neoadjuvant chemotherapy was found to have 
direct relation with prognosis. At 9 years of follow up the disease free 
survival rate in patients achieving a complete pathologic response in the 
preoperative arm (no evidence of tumor at surgery) was 75% in contrast to 
58% in patients who had any residual invasive disease left after 
chemotherapy. 
In practice, the neo adjuvant chemotherapy is used routinely for 
patients with inoperable LABC. This includes inflammatory breast cancer,  
huge, fixed or erosive inoperable lesions, and advanced, fixed node with arm 
edema. These patients will then undergo  surgical procedure, radiation 
therapy, and additional systemic chemotherapy.2 
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ANATOMY 
 
The paired mammary gland develops from remnant milk ridge in the 
pectoral region. Breast is a highly modified sudoriferous gland that develops 
as ingrowth from ectoderm and form Acini & Duct. The supporting 
vascularised connective tissue takes derivation from the mesenchyme. By 
birth lactiferous duct open into mammary pit. 
 
The mature breast is overlying the second to Sixth rib and having 
medial boundary at lateral border of the sternum and lateral boundary at 
anterior axillary line. 
 
Lobule is the basic structural unit of mammary gland. The size and 
number of the lobule differ enormously. They are numerous in young 
women. From 10 to 100 lobules empty via ductules into Lactiferous duct. 
 
Cooper’s ligaments are hollow conical projections of fibrous tissue 
filled with mammary tissue and the apices of the cones are firmly attached to 
the superficial fascia and skin.2 
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BREAST DEVELOPMENT AND PHYSIOLOGY 
 
Before puberty, the mammary gland is mainly formed by dense 
fibrous tissue and scattered ducts, lined with epithelium. Pituitary 
gonodotropins  raise serum estrodial concentrations during puberty. In the 
breast there is increased deposition of fat forming new ducts which is done  
by  branching and elongation of lobular units. This is the first appearance of 
lobular units. This process of cell division and cell growth  depends upon the 
estrogen, progesterone and adrenal Hormones. Post pubertal breast contains 
fat, lactiferous duct, stroma and lobular units. During the period of menstrual 
cycle the breast epithelium and lobular stroma, undergo cyclic stimulation. 
The dominant process is alteration of morphology and hypertrophy.2 
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INVESTIGATIONS 
DIAGNOSTIC  MAMMOGRAPHY 
Also called consultative or problem solving. It is indicated when there are 
clinical findings such as palpable lump or abnormal results on a screening 
examination 
Capabilities: 
-Can define the nature of many breast abnormalities. 
- Can identify unexpected malignancy. 
- Can identify multi focal disease. Indications of Diagnostic mammography; 
- Over 30 years 
- With/without lump before performing biopsy. 
- To Detect unexpected lesions of ipsilateral/contralateral breast. 
- To Identify   the     intraductal   component   of   a   palpable   invasive 
carcinoma. 
- To detect carcinoma in contra lateral breast after mastectomy. 
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- After surgery before radiotherapy to document all the calcification were 
removed 
- At 6 months interval for 2 years after lumpectomy in later years. 
Normal findings 
1) Four categories 
1) Breast entirely fat. 
2) Scattered fibro glandular densities. 
3) Breast tissue is heterogenetically dense. 
4) Extremely dense. 
Abnormal findings 
1.Masses and calcifications are the most common abnormality 
encountered on mammograms and radiographic features of these abnormalities 
are important clues to their etiology. In standard report these masses and 
microcalcifications indicate likelihood of malignancy, other findings include 
finding of new evolving lesions. 
- Bilateral asymmetrical distribution of fibroglandular tissue. 
- Architectural distortion. 
- Nipple retraction. 
- Axillary LN enlargement. 
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DIGITAL  MAMMOGRAPHY 
 
- This type records the radiography image electronically in a digital format 
rather than a film. 
- It is left in computer and  displayed on fluorescent monitor. 
ULTRASOUND 
5) Useful  in  young  women  with  dense  breast tissue. 
• Distinguish cysts from solid lesion. 
• Used to localise impalpable areas of breast pathology. 
6) Although  USG  is  not  efficacious  as  a  screening  modality,  combined 
mammography and USG pick up more cancers than mammography alone. 
 
COMPUTERISED TOMOGRAPHY 
7) These   play   a   major   role   in   evaluating   the   axilla,   medistinum   and 
supraclavicular areas for adenopathy and may aid in clinical staging of 
malignant processes. Apart from this CT have no role in carcinoma breast 
management.  
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Mammogram ,before and after NACT 
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MAGNETIC RESONANCE IMAGING 
MRI is of increasing interest in number of setting. 
• It can be useful to distinguish scar from recurrence in women who have 
previous conservation for cancer (although it is not accurate within 9 months 
of radiotherapy because of abnormal enhancement). 
• It is best imaging modality for the breast of women with implants. 
• It is proven to be useful as a screening tool for  high risk women (because of 
family history). 
• It  is  less  useful  than  ultrasound  in  the  management  axilla  both  in  
primary breast disease and recurrent disease. 
 
THERMOGRAPHY 
8) The  heat  emission  from  the  breast  surface  is  measured  as  infra-red 
radiation and then recorded. It is then displayed on a photographic 
plate/cathode 
 
9) ray tube. It is based on the metabolism and vascularity of the breast tissue 
and is increased in infection and some malignancy. 
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INVASIVE TESTS 
ASPIRATION CYTOLOGY 
 
10) Involves use of a fine needle with a syringe to aspirate cells from a 
suspicious area, smearing them on a glass slide fixing them immediately  to 
prevent air drying and then staging for cytology. The technique of aspiration 
cytology evolved from pretty easy aspiration from any needle to  an  
elaborate system following a set of rigid rules. The purpose of these was to 
optimise the yield and making the interpretation easier and more reliable. 
11) Instruments used are disposable plastic needles  of varying length and of 22-
26 gauge are used. Plastic syringes are used to create vacuum, the syringe 
can be attached to CAMEO syringe holder so as to perform single hand 
aspiration, and the advantage of this is that the other hand is used for fixation 
of the target.  
Procedure 
12) The lump is immobilized and if possible the skin over the lesion is stretched 
and cleaned with spirit, so that the needle reaches the target easily. The 
instrument is introduced into the lesion, then vacuum is created by about 2-3 
ml, and the needle is moved back and forth 5-6 times. By this time tissue is 
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seen at the hub of the needle, if not seen then needle is withdrawn from the 
target till the subcutaneous tissue and redirected in other direction to repeat 
the same procedure. 
13) Then the syringe is withdrawn filled with air and needle is  brought  in 
contact with the slide and one drop of tissue is deposited on one, tissue is 
spread with cover slip or a haematological smear is prepared if blood or 
aspirate is more. 
14) Following the air dried  preparation  slide is stained with wrights/wrights 
Giemsa/May Grunnwald Giemsa. If not air-dried it is immediately fixed 
with 95% alcohol and staining is done with H&E stain/with pap stain. 
15) Combination of physical examination, mammography and FNAC will 
produce a diagnostic accuracy approaching 100%. 
16) FNAC is done in palpable mass, mass on mammogram. Sensitivity of the 
test is approximately 80%, false negative varies b/w 2-10%.25 
17) Axillary US – FNAC reliably detect the node metastasis arising from both 
primary invasive ductal and lobular tumours. 
Advantages 
• Less expensive 
• Less invasive 
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Complications of FNAC 
• Growing out of tumor along needle tract, which is less in case of calibre < 
20 gauze. 
• Acute mastitis 
• Pneumothorax 
• Haematomas 
• Interval  of  weeks  required  b/w  FNAC  and  mammography  as  they  
form hematomas and result in false positive mammographic studies. 
 
CORE NEEDLE DIRECTED BIOPSY 
 
- Large bore needles are often used 
- More invasive 
- Better accuracy 
- Can perform receptor determinations 
- Can be done stereotactically 
- USG-guided   core   biopsy   used   for   preoperative   axillary lymph node 
staging 
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CHEMOTHERAPY DRUGS 
The most commonly used drugs in the chemotherapy of carcinoma 
breast are. 
 Cyclophosphamide 
 Methotrexate 
 5 Fluorouracil (5-FU) 
 Doxorubicin 
 Taxanes 
 Paclitaxel 
 Docetaxel 
Cyclophosphamide 
This alkylating agents have cytotoxic and radiomimetic actions. Act 
on dividing as well as resting cells. Cyclophosphamide has prominent 
immunosuppressant property. 
Dosage: 2-3 mg/kg per day.Toxicity: Hemorrhagic cystitis. 
Methotrexate 
It is one of the highly efficacious anticancer drug. It inhibits 
dihydrofolate reductase(DHFR) blocking the alteration of dihydrofolic acid 
to tetrahydrofolic acid. Methotrexate acts via cell cycle  – kills cells in S 
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phase.Methotrexate    inhibits deoxyribo nucleic acid synthesis. 
Methotrexate also affects ribo nucleic acid and protein formation. 
Toxicity –suppression of Bone marrow. 
 
Fluorouracil (5-FU) 
Fluorouracil (5-FU) is converted to the corresponding nucleotide 5-
fluoro 2-deoxyuridine monophosphate.This component acts by inhibiting 
thymidylate synthetase and inhibits the change of deoxyuridilic acid to 
deoxythymidylic acid. It affects even when the cell is in the resting stage 
though rapidly multiplying ones are more susceptible. 
Toxicity : Bone Marrow and G.I.T.intolerance. 
Dosage : 12 mg/kg per day 
 
Doxorubicin 
This is obtained from microorganisms which have prominent 
antitumour activity. Practically all of them collect between DNA strands and 
interfere with its template function. It has mutagenic and carcinogenic 
properties. Maximum action  occurs in S phase. 
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Toxicity : Cardiotoxicity, Marrow depression, alopecia, stomatitis and 
vomiting. 
 
Taxanes 
Docetaxel 
It enhances polymerization of tubulin, a mechanism opposite to that of 
vinca alkaloids. 
Toxicity :  Neutropenia 
  Neuropathy 
  Hypotension 
  Arrhythmias 
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PATHOLOGY 
Breast cancer originates from the epithelium present in the terminal 
duct lobular unit of the mammary tissue. Those remaining within the 
basement membrane are classified as “in Situ” and have characteristic 
patterns as do invasive cancers which disseminate beyond the basement 
members. 
Invasive cancers are now classified as 
No special types (N.S.T. not otherwise specified) or special types. 
• Lobular 
• Tubular 
• Medullary 
• Mucoid 
• Papillary 
Which may have characteristic histopathological features and some of 
which may have a better prognosis. For cancer of NST, prognosis is related 
to tumor grade I, II and III based on gland formation, nuclear pleomorphism 
as originally described by Scarff, Bloom, P.Richardson. 
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Among invasive cancers  80% is NST, 10%is Lobular and the 
remaining 10% constitutes tubular, medullary, mucoid, papillary or other 
even rare types. “Lymphatic or vascular invasion on histological assessment 
is also a marker for both local and systemic recurrence.” Patients with 
perineural invasion or extensive (>25%) in situ cancer within the tumor 
mass are more likely to develop local recurrence. 
Metastatic spread from breast carcinoma is via lymphatic channel to 
regional lymph nodes. Lymphatic and vascular invasion in the breast tissue 
is suggestive of the propensity of the cancer to spread to distant metastatic 
sites. 
 
RISK FACTORS FOR BREAST CANCER 
Factors important in populations, 
• Age at menarche(onset of menstrual cycle) and menopause 
• Parity(no of births) 
• Age at first birth 
• Breast feeding 
•  hormonal medications 
• Alcohol consumption 
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FACTORS IMPORTANT IN INDIVIDUAL PATIENTS 
• Gender 
• Age 
• Family History 
• H/o Previous Breast Cancer 
 
HISTOLOGICAL RISK FACTORS 
• Proliferative breast disease 
• Atypical ductal Hyperplasia 
• Atypical Lobular Hyperplasia 
• Lobular carcinoma in Situ. 
 
GENETIC RISK FACTORS 
5 to 10% of carcinoma breast are due to inheritance of germline 
mutations, which mainly occurs in BRCA 1 and BRCA 2. Carcinoma due to 
mutation of thse are  autosomal dominant disorder with variable degree of 
penetrance. BRCA 1 is situated on chromosome 17q. BRCA 1 and BRCA 2 
act as tumor suppressor genes. For each gene, loss of both alleles is 
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necessary for the initiation of tumour. BRCA -1 associated carcinoma breast  
are   histologically IDC (invasive ductal carcinomas). These are poorly 
differentiated tumours and the hormone receptor status for these tumours are 
usually negative. Tumours due to BRCA -1 mutation  have some unique 
clinical features.These tumours have early age of onset when compared with 
sporadic cases; there is higher chance of bilateral breast cancer. The other 
cancers associated with BRCA-1 mutation are ovarian tumour ,colonic 
malignancy and prostatic tumours. 
 
BRCA -2 is located on chromosome 13q. Its associated carcinoma 
breast is IDC. This  tumour histology belongs to well differentiated which 
also  expresses more hormone receptors than BRCA-1 associated tumours. 
Breast tumour associated with BRCA -2 mutation has the characteristic 
feature of late onset. It has high chance of bilateral breast cancer. The 
associated cancers are from ovary, prostate ,colon, , pancreas, GB, bile duct, 
and stomach malignancy along with  melanoma sometimes. 
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CLASSIFICATION OF PRIMARY CARCINOMA BREAST 
Non Invasive Epithelial Cancers 
• Lobular Carcinoma in Situ(LCIS) 
• Ductal carcinoma in Situ(DCIS) 
Invasive Epithelial Cancers 
• Invasive ductal carcinoma(IDC) (10-15%) 
• Mucinous tumours (2-3%) 
• Medullary tumours (5%) 
• Adenoid cystic tumours 
• Metaplastic carcinoma (1-2%) 
• Invasive Cribriform carcinoma (1-3%) 
• Invasive papillary carcinoma (1-2%) 
MIXED CONNECTIVE EPITHELIAL TUMORS 
• Phyllodes tumor 
• Carcinoma 
• Angio sarcoma 
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STAGING OF BREAST CANCER 
Breast cancer stage is determined by the results of surgical resection 
and imaging studies. The classification of Carcinoma breast is done with the 
TNM classification system, which concerns different patterns of breast, 
nodal, and distant tumor stages for prognostic purpose. The American Joint 
Committee on Cancer (AJCC) is widely used, which is on the basis of 
primary tumor (T), lymph node  status (N), distant metastases if any  (M), It 
is regularly updated to indicate current understanding of disease course. The 
most recent updates have incorporated  sentinel node biopsy and include 
classification of the size of metastatic deposits in sentinel nodes, as well as 
the number and location of regional node metastases. The following table 
presents the TNM working guide. 
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AMERCAN JOINT COMMITTEE ON CANCER STAGING SYSTEM 
FOR BREAST CANCER, 2002 
(p) T (Primary Tumor) 
Tis  Carcinoma in situ (lobular or ductal) 
T1  Tumor < 2cm. 
T1a  Tumor > 0.1cm, < 0.5 cm. 
T1b  Tumor > 0.5 cm, < 1cm 
T1c  Tumor 1cm, < 2cm. 
T2  Tumor > 2cm, < 5cm. 
T3  Tumor >5cm 
T4  Tumor  any size which involves chest wall or skin 
T4a  Tumor extending to the chest wall (excluding the 
pectroalis) 
T4b  Tumor involving the skin 
T4c  T4a and T4b 
T4d  Inflammatory Ca 
(p) N (Nodes) 
N0  No regional node involvement, no special studies 
N0 (i-) No regional node involvement, negative IHC 
N0 (i+) Node(s) with isolated tumor spanning < 0.2mm. 
N0 (mol-) Negetive node(s) histologically, negative PCR 
N0 (mol+) Negetive node(s) histologically, positive PCR 
N1 Metastasis involving 1-3 axillary nodes and/or int. 
mammary positive by biopsy. 
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N1 (mic) Micrometastasis (>0.2mm, none >2.0mm) 
N1a  Metastasis involving 1-3 axillary nodes 
N1b  Metastasis in internal mammary node by sentinel biopsy 
N1c Metastasis involving 1-3 axillary nodes and internal 
mammary by biopsy. 
N2 Metastasis to 4-9 axillary nodes or internal mammary 
clinically positive, without axillary metastasis. 
N2a  Matastasis to 4-9 axillary nodes, atleast 1>2.0mm 
N2b  Internal mammary clinically apparent, negative axillary  
 
Nodes. 
N3 Metastasis to > 10 axillary nodes or combination of 
axillary and int. mammary metastasis. 
N3a  > 10 axillary nodes (>2.0 mm), or infraclavicular nodes. 
N3b Positive int. mammary clinically nodes with internal 
mammary positive by biopsy. 
N3c  Metastasis to ipsilateral supraclavicular nodes. 
 
 
M (Metastasis) 
M0  No distant metastasis 
M1  Distant metastasis 
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AMERICAN JOINT COMMITTEE ON CANCER STAGE 
GROUPING 
STAGE TNM 5-YEAR SURVIVAL RATE(%) 
0  Tis, N0, M0  100 
II T1, N0, M0  100 
IIA 
T4, N1, M0  
T1, N1, M0  
T2, N0, M0 
92 
IIB 
T2, N1, M0 
         T3, N0, M0 
81 
IIIA 
T0, N2, M0  
T1, N2, M0 
T2, N2, M0 
T3, N1, M0 
T3, N2, M0 
67 
IIIB 
T4, N0, M0  
T4, N1, M0 
T4, N2, M0 
54 
IIIC Any T, N3,M0 20 
IV Any T, any N, M1 1 
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REVIEW OF LITERATURE 
 
Neo Adjuvant Chemotherapy was first introduced in 1973 in the 
Milan cancer institute aimed at achieving prompt tumor shrinkage. NSABP 
– 18 in 1988 clearly documented the usefulness of preoperative 
Chemotherapy in tumor shrinkage and thereby avoiding mutilating 
surgeries.18 
 
An objective response to neo adjuvant chemotherapy in primary 
lesion provide important in vitro evidence that this therapy being used has 
antitumor activity. Tumor at remote sites will be sensitive as well. 
Various chemotherapy combinations have been described in literature. 
Over all, clinical response rates vary in different studies between 60% to 
90% one of the frequently used combination is 5 FU, Doxorubicin, 
cyclophosphamide. 
In 1978, Bull et al showed a response rate of 82% to FAC regimen 
when compared with 62% response rate of 5–fluorouracil, methotraxate, 
cyclophosphamide.11 In a study of 372 patients who received NACT with 4 
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cycles of FAC regimen Kuerer showed a complete in 12%.12 Boti in the 
group containing 56 patients showed a response rate of 82%.13     
The response rate in European organization for research and treatment 
of cancer breast corporative group trail (EOPTC) in 1991 using 4 cycles of 
pre-operative 5 –fluorouracil, epirubicin, cyclophosphamide was only 49%. 
Newer chemotherapeutic combinations with docetaxel have shown 
significant better response rates.14 
Tables showing various trials and its results 
AUTHORS 
No.of 
Patients 
Drugs Response 
Complete 
Response 
Wolmark et 
al 
1523 AC 80 13 
Miller et al 40 A+D 85 16 
Bear et al 
805 
804 
AC+D 
AC 
91 
86 
26 
13 
 
AC  – Adriamycin, Cyclophosphamide 
FAC  – 5-fluorouracil, adriamycin and cyclophosphamide 
D  – Docetaxel 
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RESPONSE ASSESSMENT 
The assessment of response of tumor to Neo adjuvant 
chemotherapy is done by clinical and pathological tools. Clinically tumour 
response is mainly assessed by the modalities like physical examination, 
mammography, ultrasonography, CT Scan, MRI and PET Scan. Studies 
assessing the accuracy of these modalities have shown conflicting results. 
Herrada studying 100 patients compared clinical examination, 
ultrasonography and Mammography in the assessment of tumor response.18 
Physical examination was found to be the best predictor of size of primary 
tumor (p=0.0003) and its efficiency enhanced if combined with sonography 
(p=0.021).  
 
In retrospective analysis of 189 patients, Chagpar et al found only 
moderate usefulness for clinical examination, USG, and mammography in 
picking residual tumor size after neoadjuvant chemotherapy with correlation 
coefficients slightly over 0.4 for all modalities.19 Moyses et al studied the 
efficiency of  CECT  in the prediction of remaining tumour after NACT in 
43 patients and found CECT measurement or residual tumor correlated 
satisfactorily with pathologic findings (correlation coefficient was 0.69). 
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However, clinical and mammographic correlations were globally 
unsatisfactory (0.49 and 0.28 respectively).20 
 
In another study by Akashi et al concluded that Contrast enhanced 
computerised tomography is one of the best noninvasive technique for 
evaluating the extent of the remaining tumour tissue if cases of invasive 
lobular carcinoma and inflammatory breast carcinoma are excluded (R 
insertion mark 2-0.537).21 CT scan has the advantage of easy availability and 
rapidity when compared to MRI. 
 
 
    WHO CRITERIA22 
The antitumor activity of the chemotherapeutical agents is assessed by 
measuring the change in size of the tumor. The W.H.O. developed criteria to 
standardize clinical outcome in the early 1980’s. 
Complete Response 
Complete absence of disease, signs, symptoms, and biochemical 
change made by the malignancy for one month, in which period nil new 
lesions arise. 
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 Partial Response 
Reduction of 50% or above in the total volume of clinically 
appreciable lesion lasting at least one month . 
 
STABLE DISEASE –  < 50% reduction. 
Reduction or < 25% or above in the total volume of tumour  of two 
perpendicular diameter of all measurable lesions, and absence of fresh 
lesions for eight wks. 
PROGRESSION OR RELAPSE 
Increase in the volume of the 2 perpendicular diameter of any 
measurable lesion by more than twenty five percent over the size present at 
early into the study. For those who respond over the size during at time of 
maximum falling off or the appearance of new areas of tumour spread. 
However, WHO criteria is poorly reproducible as it does not describe 
methods used in measurement and selection of target lesions. In order to 
decrease the risk of measuring error and avoid overestimation of response 
rates response evaluation criteria in solid tumors (RECIST) working group 
proposed new guidelines.23 
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RESPONSE EVALUATION CRITERIA IN SOLID TUMORS 
WORKING GROUP (RECIST) 
RECIST 
Criteria offer a simplified, conservative, extraction of imaging data, 
for  clinical trials. They presume that linear measures are an adequate 
substitute for 2-D methods and register 4 response categories. 
 
Complete Response : Complete abscence of all target lesions. 
Partial Response : 
 
 
Even thirty percent reduction  in the sum of the  
Longitudinal diameter(LD) of target lesions, 
taking as reference the baseline sum LD. 
Progressive Disease : 
 
Even 20% increase in the total length of the  
Longitudinal diameter of target lesions. 
Stable Disease : 
 
 
 
Neither sufficient shrinkage to qualify for  
Partial response  nor sufficient increase to 
qualify for progressive disease, taking as 
reference the smallest sum longitudinal 
diameter  since the treatment started. 
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If greater than 10% of tumor cells stain positive for the nuclear 
receptor, the assay is reported as “positive” and a response to hormonal 
treatment is likely. There is no confirmatory evidence of receptor status 
as a useful indicator of response to NACT. 
HER -2 NEU ONCOGENE 
HER -2 / neu ocogene encodes a transmembrane tyrosine kinase that 
is the receptor for a family of polypeptide growth factors, Over 
expression implies elevated tumor behaviour, raised recurrence rates, and 
increased number of death in patients with positive nodes.32 
Zhang F et al., could not monitor a correlation between human 
epidermal growth factor-2 expression and the clinicopathological 
response to NACT in 97 patients with carcinoma breast.33 Several other 
studies have found a positive correlation between the expression of this 
oncogene with response to anthracycline based chemotherapy. 
 
The HER -2 / neu is used as a indicator, in deciding efficacy to 
trastuzumab in the distant metastasis. Currently available data shows an 
adriamycin – based regimen to be more effective in HER -2 / neu – over 
expressing tumours. 
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TOMOUR PROLIFERATION MARKER : Ki 67 
Uninhibited proliferation, which is the main feature in malignant 
transformation, can be quantified by assessing the group of cells that are 
committed to succeeding to cell cycle. Monitoring the presence of Ki 67 by 
immunohistochemistry correlates with the S phase fraction. Petit et al 
evaluated the grade of tumour, Ki-67, hormonal receptors, human epidermal 
growth factor receptor -2 and topoisomerase II alpha status as useful 
indicators in carcinoma breast patients managed with NACT with 
anthracycline . In 119 patients, the clinical outcome (OR) was 80%, and of 
complete responders (CR) was 19%. In the multivariate analysis, the 
absence of HER-2 neu expression and Ki-67 > or = 20% is a useful tool for a 
clinically complete response.30 
P53 
P53 also known as the “guardian of the genome”, is a transcription 
factor, which regulates the apoptosis. P53 has been shown to induce 
apoptosis, whereas loss P53 action has documented to increase cellular 
resistance to a number of chemotherapeutic agents. Hence, it has been used 
in various studies as a marker of response to chemotherapy. The results are 
conflicting and it relates to the type of chemotherapeutic drug used. 
 46 
 
Kandioler-Eckersberger D et al studied the p53 status of 67 patient’s breast 
tumour using both immunohistochemistry (IHC) and direct sequencing of 
the entire p53 gene. Of 17 patients with treatment failure, seven had a P53 
mutation and 14 had a positive immunohistochemistry. Only one of 
seventeen patients not showing any response to management had neither a 
mutation nor positive immunohistochemistry. In the FEC group, treatment 
failure was related to both the existence of P53 gene mutation (P=0.0029) 
and a positive IHC (P=0.0001) and these may help to predict resistance to 
anthracyclines in breast cancer. Anelli et al studied the response of breast 
cancer in 73 patients treated with paclitaxel and adriamycin. They found, 
the absent p53 expression  denotes a higher chance of responding to this 
regimen.    
However, many studies analysing p53 status by use of IHC have 
failed to show a analytical value of p53 in breast cancer. 
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MATERIALS AND METHODS 
The study was done during the period from January 2011 to June 2012 
in the department of Surgery Thanjavur Medical college and Hospital 
Thanjavur. All the patients with Breast cancer was examined clinically. 
Patients with LABC was selected for the study. 
Locally advanced carcinoma breast was defined as per AJCC staging 
and included stage IIb (T3 N0M0) Stage III A and stage III b tumours. 
Exclusion criteria included any contraindications for chemotherapy. 
INCLUSION CRITERIA 
• Stage IIb (T3N0M0) 
• Stage IIIa 
• Stage IIIb 
• LABC without any co-morbid conditions 
EXCLUSION CRITERIA 
• All early Breast Recurrence 
• LABC with Distant metastasis 
• LABC with co morbid conditions 
• Any contra indications for surgery 
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INVESTIGATIONS 
• Complete Haemogram 
• Renal Function Tests 
• Liver Function Tests 
• FNAC 
• X-Ray Chest 
• ECG 
• Ultrasonogram Abdomen 
• Echocardiogram 
 
FNAC was done to confirm the diagnosis, in all patients. Routine 
investigations like complete hemogram, renal function tests, and liver 
function tests were done. Metastatic work up was done, X-Ray chest and 
ultrasonogram abdomen. Cardiac assessment was done with 
echocardiogram for adriamycin based chemotherapy. 
Detailed history and clinical examination of the patients were carried 
out as per the proforma. Tumor size assessed clinically two longest 
perpendicular diameter and the products of the two perpendicular diameters 
 50 
 
were calculated. All Patients have taken CT scan breast before starting Neo 
adjuvant chemotherapy. 
After completion of 1st  cycle and before starting a next cycle C.T. 
breast taken to measure the Breast size. After completion of 3 cycles at the 
end of 3rd week, tumor size measured clinically and C.T.Breast taken 
regularly. 
Chemotherapy was administered after admitting the patients after 
calculating body surface area. Antiemetic pre medications which included 
ondensetron. 4 mg, Injection dexamethesone 8 mg. and ranitidine 
150mg./sq.m. 
Intravenous infusions of cyclophoshamide 600mg/m2 5 fluorouracil 
500mg/m2, adriamycin 60mg/m2. were given as per FAC regimen. Patients 
were observed for side effects and discharged on same day with oral 
ondensetron prescription for 3 days. 
Chemotherapy was repeated every 21 days after assessing the tumor 
response clinically for maximum of three cycles. After two weeks of the last 
preoperative cycle, tumour size was assessed clinically and with a repeat C.T 
Breast. RECIST criteria was used to assess the tumor response clinically. 
Patients with partial response were worked up for modified radical 
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mastectomy. The mastectomy specimens were assessed in patients who 
showed complete clinical response. All specimen showed tumor free 
margins. 
 
Patients who had complete clinical response according to WHO / 
RECIST criteria were managed with modified radical mastectomy. Patients 
who showed no response according to WHO / RECIST criteria were 
managed with Toilet mastectomy followed with adjuvant chemotherapy and 
Radiotherapy. 
 
DOSAGE AND SCHEDULE38 
Choosing the regimen 
There is no single regimen that has emerged as the treatment of choice. 
Several trials have demonstrated that a 10% - 20% higher response rate has 
been observed with Doxorubicin/Epirubicin containing regimen with an 
increase in median survival from 14-18 months and an increase in median 
time of treatment failure from 5 to 7 months. The shorter duration of 
regimen and relative ease of administration has led to the popularity of AC 
regime and favor this regimen as the first choice of therapy. 
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Regimens 
FAC 
• 5 FU 500mg/m2 
• Adriamcycin 60mg/m2 
• Cyclophosphamide 600mg/m2 
• On day one every 3 weeks for 6 weeks 
AC 
• Adriamycin: 60mg/m2, D1 
• Cyclophosphamide: 600 mg/m2, D1 
• 4 cycles are given, once every 3 weeks 
CAF 
• Cyclophosphamide: 100 mg/m2  d, D1-14 
• Adriamycin : 30 mg/m2, D1, 8 
• 5 FU: 500mg/m2, D1, 8 
• 6 cycles are given, once in 4 weeks 
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CMF 
• Cyclophosphamide: 750 mg/m2 
• Methotrexate : 50 mg/m2 
• 5-FU: 600 mg/m2 
• Given once in every 3 weeks, for 6 cycles. 
 
FEC 
• 5 FU 500mg/m2 
• Epirubicin 50mg/m2 
• Cyclophosphamide 500mg/m2 
• On day one, every 3 weeks for 6 cycles 
 
TAC 
• Docetaxel 75 500mg/m2 on D1 
• Adriamycin 50mg/m2  on D1 
• Cyclophosphamide 500mg/m2  on D1 
• 6 cycles are given, every 3 weeks. 
 
AC-T 
• Adriamycin : 60mg/m2, D1 
• For 4 cycles once every 3 weeks 
• Followed by 
• Taxol (paclitaxel) 175mg/m2 
• Every 3 weeks for 4 cycles 
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RESULTS 
The study was conducted between 2011 August and november 2012. 
Seventy two patients who qualified for the inclusion criteria were included 
in the study. Three patients were excluded as the pre chemotherapy X-Ray 
revealed lung metastasis. Four patients lost  follow up. Five patients 
defaulted after 3 cycles of chemotherapy. Hence 9 patients out of 69 did not 
complete the treatment. 60 patients who were included in the study 
completed the treatment. 
 
DEMOGRAPHIC PROFILE 
Clinical parameters of 72 patients were analysed. The range of 
patients age was 32 to 72 years and mean age at appearance was 55.45 years. 
6.9% patients were in the age group of < 40 years. 16.6% patients fell in the 
age group of 40-49 years & 50% fell in the age group of 50 to 59 years. 
26.5% were  above 60 years. Fifty two patients in the study group were post 
menopausal and 20 patients were pre menopausal. 
There was a predominance of left sided Breast cancer. Thirty nine 
(54.2%) patients had cancer of the left Breast where as thirty three patients 
had right sided Breast cancer (45.8%). Thirty five patients (48.9%) had 
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upper outer quadrant of the Breast. Six patients (13.93%) had tumour in the 
central quadrant. 
Thirty four patients (47.22%) had T3 tumor at presentation whereas 
38 patients (52.78%) had T4 presentation. 
Seven (9.72%) patients had stage IIb disease. Whereas 27 patients 
(37.5%) and III-a, Thirty eight (52.78) patients had III b. The mean size of 
the tumor in its longest diameter was 7.04 cms. 
 
COMPLICATIONS 
Alopecia and vomiting were the commonest side effects noted in the 
study. All the patients developed Alopecia of varying intensity. 50 patients 
had Black discoloration of nails, palms. Five patients developed anemia that 
was managed with Hematinics and transfusion. 
 
Primary tumor response to neoadjuvant chemotherapy 
65 patients were finally assessed for study of NACT in locally 
assessed Breast cancer. Out of sixty five, six patients (9.24%) had complete 
response. Thirty six patients (55.38%) patients had partial response and 23 
patients (35.36) had no response according to RECIST criteria. 
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TABLE -1 
AGE DISTRIBUTION AMONG THE PATIENTS IN THE 
STUDY GROUP 
 
 
Age No. of Cases Percentage (%) 
<40 5 6.9 
40-49 12 16.6 
50-59 36 50 
>60 19 26.5 
Total 72 100 
 
/ 
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CHART -1 
AGE DISTRIBUTION AMONG THE PATIENTS IN THE 
STUDY GROUP 
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TABLE -2 
QUADRANT DISTRIBUTION AMONG THE PATIENTS IN 
THE STUDY GROUP 
 
Quadrant No.of Cases Percentage (%) 
UO 35 48.6 
LO 17 23.6 
C 10 13.92 
UI 7 9.7 
LI 3 4.18 
Total 72 100 
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CHART -2 
AMONG THE PATIENTS IN 
THE STUDY GROUP 
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TABLE -3 
SIDE DISTRIBUTION AMONG THE PATIENTS IN THE 
STUDY GROUP 
 
 
 
 
 
 
Side No.of Cases Percentage (%) 
Right 33 54.2 
Left 39 45.8 
Total 72 100 
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TABLE -4 
DISTRIBUTION OF PATIENTS ACCORDING TO TNM 
CLASSIFICATION 
 
TNM Classification No.of Cases Percentage (%) 
T3N0M0 7 9.72 
T3N1M0 23 31.94 
T3N2M0 4 5.55 
T4bN0M0 5 6.94 
T4bN1M0 25 34.75 
T4bN2M0 5 6.94 
T4bN2M1 3 4.16 
Total 72 100 
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CHART -3 
DISTRIBUTION OF PATIENTS ACCORDING TO TNM 
CLASSIFICATION 
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TABLE -5 
DISTRIBUTION OF PATIENTS ACCORDING TO T-
STAGING OF TNM CLASSIFICATION 
 
 
 No.of Cases Percentage (%) 
T3 34 47.22 
T4 38 52.78 
Total 72 100 
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CHART -4 
DISTRIBUTION OF PATIENTS ACCORDING TO T-
STAGING OF TNM CLASSIFICATION 
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TABLE -6 
DISTRIBUTION OF PATIENTS ACCORDING TO CLINICAL 
STAGING 
 
Stages No.of Cases Percentage (%) 
Stages IIb 7 9.72 
Stage IIIa 27 37.50 
Stage IIIb 38 52.78 
Total 72 100 
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CHART -5 
STAGING 
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TABLE -7 
RESPONSE RATE OF NACT ACCORDING THE RECIST 
CRITERIA 
 
Response No.of Cases Percentage (%) 
Complete 6 9.24 
Partial 36 55.38 
No Response 23 35.38 
Total 65 100 
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CHART -6 
RESPONSE RATE OF NACT ACCORDING THE RECIST 
CRITERIA 
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TABLE -8 
TYPE OF SURGERY DONE 
 
Surgeries No.of Cases Percentage (%) 
Modified Radical 
Mastectomy 
47 78.33 
Toilet Mastectomy 13 21.67 
Total 60 100 
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CHART -7 
TYPE OF SURGERY DONE 
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TABLE -9 
DISTRIBUTION OF PATIENTS ACCORDING TO SIZE OF 
TUMOUR 
 
 
Mean size of Tumour for 
Complete Response    : 5.53 
Partial Response   : 6.33 
No Response   : 8.83 
 
Mean  : Before NACT  After NACT 
        7.04           3.54 
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DISCUSSION 
 
Over the last decades Neo adjuvant  Chemotherapy has changed the 
way in which locally advanced carcinoma breast is managed. 
The study was designed with the aim of assessing the efficacy of Neo 
adjuvant chemotherapy in the population in and around TMCH, 
THANJAVUR 
An objective response to neo adjuvant chemotherapy in primary 
lesion provides important in vitro evidence that this therapy being used has 
antitumor activity. Tumor at remote sites will be sensitive as well. 
Various chemotherapy combinations have been described in literature. 
Over all, clinical response rates vary in different studies between 60% to 
90% one most commonly used combination is 5-fluorouracil, adriamycin, 
cyclophosphamide. 
In 1978, Bull et al showed a response rate of 82% to FAC regimen 
when compared with 62% response rate of 5-fluorouracil, methotraxate, 
cyclophosphamide. In a study of 372 patients who received NACT with four 
 73 
 
cycles of  FAC regimen Kuerer showed a complete response in 12%. Boti et 
al in fifty six patients showed an overall outcome of 82%. 
 
The response rate in European organization for research and treatment 
of cancer breast corporative group trial (EORTC) in 1991 using 4 cycles of 
pre-operative 5 – fluorouracil, epirubicin, cyclophosphamide was only 49%. 
The recent introduction of chemotherapy regimens using docetaxel have 
been shown to have significant better response rates. Expecting same line of 
better results we have followed F.A.C regimen in our study in TMCH, 
Thanjavur. 
 
Seventy two patients with LABC breast were included in the study. 
Three patients have metastasis in the X-Ray chest. Four patients lost follow 
up. Five patients did not undergo mastectomy. Finally sixty patients 
completed the treatment protocol. 
 
The reasons for this drop out could be the need for multiple hospital 
visits and side effects of the chemotherapy. Even in western studies like 
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NSABP B – 27 only 80% of the total patients inducted in the study had 
completed the treatment. 
 
DEMOGRAPHIC PROFILE 
The mean age at presentation to hospital 55.45 years with majority in 
50-59 years. The mean longest diameter of tumor at presentation in this 
study was 7.04 and after NACT was 3.54. 
 
RESPONSE TO NEO ADJUVANT CHEMOTHERAPY 
All patients with LABC received three cycles of FAC regime with 
cyclophosphamide 600mg/m2. 5FU 500mg/m2, adriamycin 60mg/m2 at 
intervals of 21 days. 
 
In a study on preoperative chemotherapy conducted in patients with 
operable breast cancer, a response rate of 80% and complete pathologic 
response in 13% was seen. 
 
The following are taken as predictor of response. 
i. Clinical : The size of Tumor. 
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Grave signs such as oedema and ulceration. Nodal Status : Size 
Number, Group and fixity  of Tumor. 
 
ii. Epithelial elements i.e. FNAC 
Expression of differentiation of neoplastic cells Grading and 
outcome pre and post operatively size and shape staging of 
neoplasam. 
 
iii. Investigations : 
• CT chosen, as it is the most accurate non – invastive 
technique of identifying the extent of residual carcinoma. 
• LFT is repeated to find out any rise in Alkalaine 
phosphatase. 
• X-Ray used as the pre and post op.skeletal survey. 
 
SIZE AS A PREDICTOR OF RESPONSE 
The mean size of tumor in patients with complete response was 5.53, 
6.33 for partial response, and 8.83 for no response. 
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Kuerer et al has found smaller tumor is  associated with a complete 
pathological response in 372 patients receiving adriamycin  based neo 
adjuvant chemotherapy (P.value <0.01). The size of the primary tumor has 
also been found to be associated with survival. 
 
Valagussa  shown the five year survival rate were 65%, 36%, 16% for 
tumor volume measuring <5cm, 5-10cm and >10cm respectively. 
 
After completion of three cycles of NACT the tumor size grave signs 
like oedema and ulceration decreased in 78% of cases fixity became less. 
 
AXILLARY NODE STATUS AND RESPONSE 
Patients with clinically negative axilla had a significantly better 
chance of having complete response than that in patienst with clinically 
positive axilla. Out of 48 patients who were node positive 20 patients 
became clinically negative after completion of 3 cycles of chemotherapy. In 
the remaining 28 patients size of the node and their number has decreased. 
Among the specimen of 28 patients, 10  were less than 2 node positive for 
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tumor. 18  were positive for more than 4 nodes. Node positive patients were 
treated with adjuvant chemotherapy and radiotherapy. 
 
 
 
SKIN INVOLVEMENT AND RESPONSE 
Tumors without skin involvement showed a significantly better 
response to chemotherapy assessed by W.H.O. criteria. The better response 
shown by tumors with smaller size clinically node negative and no skin 
involvement suggest that tumor cells may became more resistant as the 
tumor grows. 
 
This is in concordance with the Goldie – cold man Hypothesis that the 
likehood that resistant cells are present is a function of tumor size (or) the 
number of tumor cells and the spontaneous mutation rate of the cells. 
Histologically all the tumours turned out to be infiltrating ductal carcinoma. 
 
This study shows that the NACT with FAC regimen effects dramatic 
regression of the Breast lesion in apparently 70% to 80%. The index lesion 
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and axillary metastasis have disappeared following the 3 cycles of FAC 
regimen. 
 
The study also shows that the tumor shrinkage and disappearance 
increased the sense of well being among of the patients, their confidence 
level enhanced: After the NACT Technical operability of the tumor has 
improved What seemed:- Inoperable become Amenable to modified radical 
mastectomy in 60 to 70% of patients. 
 
SURGERY 
Out of sixty patients who had completed the 3 cycles of Neo adjuvant 
chemotherapy. Six patients (10%) who had complete response underwent 
modified radical mastectomy. The other forty one patients (68.33%) also 
underwent modified radical mastectomy totally accounting for 78.33% and 
remaining 13 patients (21.6%) underwent Toilet mastectomy. 
 
After establishing the loco regional control by above surgeries, these 
patients were followed up by adjuvant chemotherapy and adjuvant 
radiotherapy. 
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CONCLUSION 
 Locally advanced Cancer Breast tops among  all the Carcinoma  
Breast attending surgical outpatient department  in 
TMCH,THANJAVUR. 
 Locally advanced Cancer Breast with axillary node and grave 
signs like oedema and ulceration is one of the presentation 
among all Carcinoma patients attending surgical Outpatients of 
TMCH,THANJAVUR. 
 After Neo adjuvant chemotherapy for LABC with FAC regimes 
most of the Inoperable advanced Breast cancer became 
Technically operable. 
 Appropriate surgery done with or without post operative events 
in 78% of patients who became symptom free, and their quality 
of life improved. Survival period is prolonged and their disease 
free survival also improved. 
 68.3% patients who  partially responded after Neo adjuvant 
chemotherapy were managed by M.R.M. 10% patients who 
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responded completely also managed with modified radical 
mastectomy. 21.6% patients who are non responders clinically 
after Neo – adjuvant chemotherapy are treated with Toilet 
mastectomy. 
 In a nut shell neo adjuvant chemotherapy for locally advanced 
Breast cancer definitely paves the way for successful surgery in 
most cases, there by making patients free from agonizing 
symptoms, giving satisfactory quality of life without much 
burden to the individual, family & society. 
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 1 
 
PROFORMA 
Name  
Age & Sex     Code No: 
Address     I.P. No: 
 
I.D No. 
 
History 
i) Duration of lump 
ii) History of benign Breast disease 
iii) Family History of 3 generations 
a) Grand Mother 
b) Mother/Aunts 
c) Sisters 
MENTRUAL HISTORY 
i) Pre menopausal 
ii) Post menopausal 
 
 
 2 
 
COMORBID DISEASE 
 
CLINICAL EXAMINATIONS 
 
STAGE OF DISEASE BY TNM BEFORE CHEMOTHERAPY 
 
STAGE OF DISEASE BY TNM AFTER CHEMOTHERAPY 
INVESTIGATIONS 
• Xray Chest 
• USG Abdomen 
• LFT 
• FNAC/True cut Biopsy 
• U.S.G. Breast 
• C.T. Breast 
SIDE EFFECTS OF THE CHEMOTHERAPY 
RESPONSE ASSESSMENTS 
i) Clinical Response 
ii) U.S.G Based 
iii) CT Based 
 3 
 
SURGERY PLANNED 
• Simple Mastectomy 
• Modified Mastectomy 
• Toilet Mastectomy 
 
 
 
 
 
 
 
S.NO NAME Age Set I.P.NO SIDE TNM STAGING 
Tumour 
size 
before 
nact 
Tumour 
size after  
NACT
HPE U.S/C.T Surgery
1 Kasthuri 32 1374927 R T3N2M0 5x5.7 IDC C.T MRM
2 Sharmila 43 1381018 R T4bN0M0 8x7.1 4x3.1 IDC C.T MRM
3 Selvi 47 1387334 R T4bN0M0 8x7.1 5.4x4.5 IDC C.T TM
4 Ammuni 45 1391296 R T3N0M0 5.5x6 2x1 IDC C.T MRM
5 Vaduvammal 55 1403147 L T4bN1M0 8.8x8 4.4x4 IDC C.T MRM
6 Ranjitham 35 1412541 L T3N1M0 8x8.5 3x4.6 IDC C.T MRM
7 Preetha 61 1420801 R T3N1M0 5.9x5.5 IDC C.T MRM
8 Susila 54 1393514 R T3N1M0 6.5x6 3x3 IDC C.T MRM
9 Vasantha 31 1395330 L T3N1M0 5x6.0 2x3 IDC C.T MRM
10 Thangavel 69 1396009 R T4bN0M0 8x8 3.8x4 IDC C.T MRM
11 Marry 54 1422688 L T3N1M0 10x10 5x6 IDC C.T MRM
12 Saroja 33 1028097 L T3N2M0 5x5.2 IDC C.T TM
13 Chellammal 58 1033259 R T3N1M0 6x5 3x2.5 IDC C.T MRM
14 Gangammal 72 1034900 L T4bN1M0 6x6.5 3x2 IDC C.T MRM
15 Selvanayaki 36 1035346 R T3N2M0 6.5x6 2x3 IDC C.T MRM
16 Amutha 65 103641 R T4bN1M0 7x6.4 3.5x3.2 IDC C.T MRM
17 Rajamani 42 1062449 L T4bN0M0 9x7 4.5x4.8 IDC C.T TM
18 Rani 64 1064003 R T3N2M0 6.7x7 3.4x3.5 IDC C.T MRM
19 Alli 51 1067693 L T4bN1M0 8.2x7 4x3.5 IDC C.T MRM
20 Thenmozhi 57 1041082 L T4bN0M0 8x7 4.4x3.9 IDC C.T TM
21 Saroja 56 1351357 R T4bN1M0 8.5x7.4 4x3.1 IDC C.T MRM
22 Dhanalakshmi 59 1356137 L T3N0M0 5x5.8 IDC C.T MRM
S.NO NAME Age Set I.P.NO SIDE TNM STAGING 
Tumour 
size 
before 
nact 
Tumour 
size after  
NACT
HPE U.S/C.T Surgery
23 Chandra 69 1357195 R T4bN1M0 5x3 2x1.3 IDC C.T MRM
24 Kanaga jeyam 47 1360291 L T4bN1M0 8x8.5 4x4.2 IDC C.T MRM
25 Santha 54 13601404 R T3N1M0 8x5.8 3.8x4 IDC C.T TM
26 Mala 64 1365820 L T3N0M0 6x4 3x2 IDC C.T MRM
27 Panchavarnam 57 1368513 R T4bN1M0 7.5x7 3.5x3.5 IDC C.T MRM
28 Rajalakshmi 71 1377327 L T3N1M0 5x5.1 IDC C.T MRM
29 Arokya mary 63 1383626 R T4bN1M0 8.6x8 4.4x4.2 IDC C.T MRM
30 Ayiranvalli 58 1384888 L T3N1M0 4x3 2x1.5 IDC C.T MRM
31 Mookayi 48 1385488 R T4bN1M0 9.8x7.2 5x4 IDC C.T TM
32 Chipa 52 1387499 L T3N1M0 5x4 2.5x2 IDC C.T MRM
33 Ponnarani 55 1391401 R T3N1M0 4x4 1.5x2 IDC C.T MRM
34 Subalaxmi 54 1401423 R T3N1M0 6x5 3x2 IDC C.T MRM
35 Santha 65 1407112 L T4bN1M0 9.8x7 6.5x3.4 IDC C.T TM
36 Chinnathal 40 1412862 R T3N1M0 7x5 3.5x2 IDC C.T MRM
37 Jeenath begam 54 1416167 R T3N1M0 8x4.5 4.3x2.4 IDC C.T MRM
38 Purphavalli 53 1388094 L T4bN1M0 4x3.5 2x1.4 IDC C.T MRM
39 Mahamayee 66 1389444 L T3N1M0 5x4 2.5x1.2 IDC C.T MRM
40 Irudaya mary 48 1396191 R T4bN1M0 10x7.3 6.1x4.2 IDC C.T TM
41 Revathy 67 139906 R T4bN1M0 9x6.4 5.2x4 IDC C.T TM
42 Amarya 51 1399176 L T3N0M0 5.5x5 IDC C.T MRM
43 Rajam 52 1403687 L T4bN1M0 6x3.2 2x1.1 IDC C.T MRM
44 Vijaya 55 1411006 L T4bN2M0 6.3x4 3.2x1.5 IDC C.T MRM
S.NO NAME Age Set I.P.NO SIDE TNM STAGING 
Tumour 
size 
before 
nact 
Tumour 
size after  
NACT
HPE U.S/C.T Surgery
45 Varammal 46 1414818 R T4bN1M0 9x6.2 5x4.2 IDC C.T TM
46 Pooja 58 1419711 R T4bN1M0 9x3.2 5.4x2.2 IDC C.T MRM
47 Magadevi 53 1422994 R T3N0M0 5.6x3 2x1.2 IDC C.T MRM
48 Rani 62 1360775 L T4bN1M0 7x5.2 4x3.2 IDC C.T TM
49 Uma 41 1389729 L T3N1M0 5x6 2x1.8 IDC C.T MRM
50 Santhi 57 1390415 R T3N1M0 6.1x6.5 3x2.5 IDC C.T MRM
51 Vimali 68 1391050 R T3N1M0 6x4 2x1.5 IDC C.T MRM
52 Lakshmi 52 1406301 L T4bN1M0 6.2x7.1 3.1x3.5 IDC C.T MRM
53 saradha 58 1390358 L T4bN1M0 8.4x8.2 5.4x4.2 IDC C.T MRM
54 Muthulakshmi 63 1391638 L T3N1M0 5x4.8 2.5x2.0 IDC C.T MRM
55 Andal 55 1391643 L T4bN1M0 7x4 4x3 IDC C.T TM
56 Kasthri 52 1391582 R T4bN1M0 9x7 5x4 IDC C.T -
57 Rajammal 54 1392857 R T4bN1M0 10x7 6x4 IDC C.T -
58 Paiyanayaki 57 1397571 L T3N0M0 6x5 3x2.1 IDC C.T MRM
59 Andal 63 1391643 L T4bN2M0 8x9 4.5x6.0 IDC C.T -
60 Sakunthalal 58 1401080 R T4bN2M0 9x9 5x6.5 IDC C.T -
61 Moomina devi 53 1406536 L T3N1M0 6.6x4.5 2.3x2.3 IDC C.T MRM
62 Kamali 45 1407830 R T4bN2M0 10x8 6x5 IDC C.T -
63 Saratha 53 1410618 R T3N0M0 5x4 2x2 IDC C.T MRM
64 Vimala 51 1423428 L T4bN2M0 9x6 5x4 IDC C.T TM
65 Chitra 53 1381027 L T3N1M0 5x4 2.5x1.5 IDC C.T MRM
S.NO NAME Age Set I.P.NO SIDE TNM STAGING 
Tumour 
size 
before 
nact 
Tumour 
size after  
NACT
HPE U.S/C.T Surgery
66 Kalyani 78 1387356 R T4bN2M0 8x7 2x1.8 IDC C.T MRM
67 Kamatchi 44 1391236 L T3N1M0 5x2 3x2.5 IDC C.T MRM
68 Kanaga 75 1403151 R T3N1M0 7x3 2x1.5 IDC C.T MRM
69 Sathya 53 1412528 R T3N1M0 3x4 3.1x3.5 IDC C.T MRM
70 uma 55 1420809 R T4bN2M1 10x7 5.4x4.2 IDC C.T TM
71 Sathya bama 54 1393525 R T4bN2M0 7.6x9 2.5x2.0 IDC C.T TM
72 Jothi 64 1395398 R T4bN2M0 9.8x7.2 4.5x6.0 IDC C.T MRM
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